Regeneron Pharmaceuticals, Inc.REGN

Where REGN's Net Debt / EBITDA sits inside its own 10-year distribution, with the yearly high, low and average.

$827.72-15.75 (-1.87%)Previous close
NASDAQHealthcare

REGN Net Debt / EBITDA: current value, 10-year range and year-by-year history

Net Debt / EBITDA History

Historically priceyAbove avgAround avgBelow avgHistorically cheap
REGN Net Debt / EBITDA historyREGN Net Debt / EBITDA from Sep 2023 to Jun 2026: low -0.08, high 0.15, latest -0.08.-0.1-0.030.040.10.17Sep 23Mar 24Sep 24Jun 25Dec 25Jun 26med 0.02

REGN Net Debt / EBITDA by year

Yearly range of REGN’s net debt / ebitda from 2016 to 2026. Over the full period it ranged from -0.5 to 0.3, averaging -0.1.

REGN Net Debt / EBITDA — yearly low, average, high and year-end values
YearLowAverageHighYear-end
2026-0.1-0.1-0.0-0.1
2025-0.10.00.1-0.1
20240.00.10.20.0
2023-0.20.00.1-0.0
2022-0.1-0.1-0.1-0.1
2021-0.10.10.3-0.0
2020-0.5-0.00.30.1
2019-0.4-0.3-0.1-0.3
2018-0.3-0.2-0.1-0.3
2017-0.1-0.0-0.0-0.0
2016-0.4-0.2-0.0-0.0

Get notified when REGN Net Debt / EBITDA crosses a threshold

Free — one alert setup, notifications by push, Telegram, or Discord.

How many years of operating earnings it would take to pay off the company's net debt. The most common leverage ratio — higher means more financial risk and less flexibility.

Formula(Total Debt − Cash) / EBITDA
Full guide
How to read this chart

Watch the trend more than the level. Declining ratio = deleveraging, growing financial flexibility. Rising ratio = increasing leverage, which constrains dividends, buybacks, and future investment.

Key caveats
  • Sector context is essential: 3× is aggressive for a consumer brand but normal for a regulated utility. Always compare to sector peers.
  • Large acquisitions spike the ratio temporarily — check whether the integration plan credibly drives paydown.
Pro — up to 30-year history

Unlock 10y, 15y, 20y, and 30y history with peer comparison and CSV export.